Healthcare / BiotechnologyNYSE American
$0.29
+0.01 (+3.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-5.7M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$30M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-112.5%
↓Gross Margin
48.7%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
-8.0%
FCF CAGR
—
FCF margin
-344.7%
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.3M · net income $-7.1M · FCF $-4.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $1.3M | $1.3M | $1.3M | $911000.00 | $397000.00 | $898000.00 | $4.1M | $5.1M | $2.2M | $580372.00 | $6.4M | $7.7M | $2.3M | $8.0M | $4.2M | $4.1M |
| Net Income | $-7.1M | $-7.1M | $-13.0M | $-11.5M | $-15.0M | $-8.8M | $-7.3M | $-4.1M | $-1.8M | $-1.9M | $-2.8M | $-4.6M | $-3.0M | $-2.3M | $-7.8M | $-20.2M |
| EBITDA | $-7.0M | $-7.0M | $-9.2M | $-10.9M | $-14.8M | $-8.2M | $-6.7M | $-4.6M | $-1.8M | $-1.7M | $-2.2M | $-3.6M | $-1.8M | $-1.8M | $-6.5M | $-15.1M |
| EPS | -0.09 | -0.09 | -0.22 | -0.22 | -0.30 | — | — | — | — | -0.07 | -0.17 | -0.31 | -0.37 | -0.32 | -2.66 | -13.40 |
| Gross Margin | 48.7% | 48.7% | 54.5% | 48.5% | 48.9% | 12.6% | 2.8% | 2.6% | 3.7% | 37.6% | — | — | — | — | — | — |
| Operating Margin | -585.8% | -585.8% | -728.5% | -1270.1% | -3886.1% | -971.5% | -168.6% | -90.8% | -81.6% | -354.0% | -45.6% | -56.5% | -111.2% | -30.9% | -178.9% | -390.0% |
| Net Margin | -560.3% | -560.3% | -966.5% | -1263.0% | -3782.4% | -981.2% | -179.6% | -80.1% | -81.4% | -321.7% | -44.1% | -60.1% | -133.0% | -28.0% | -184.6% | -496.8% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.03 | 0.03 | 0.01 | 0.00 | — | — | 0.06 | 0.06 | 0.02 | 0.00 | — | — | — |
| Current Ratio | 1.32 | 1.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-4.4M | $-4.4M | $-5.7M | $-7.7M | $-8.2M | $-12.3M | $-13.1M | $-3.3M | $-2.1M | $-1.5M | $-279887.00 | $-2.7M | $-1.8M | $238767.00 | $-5.0M | $-2.9M |
| Returns | ||||||||||||||||
| ROE | -112.5% | -112.5% | -177.6% | -77.2% | -62.8% | -26.9% | -27.6% | — | -22.1% | -25.4% | -20.8% | -32.4% | -22.2% | -15.6% | -52.2% | -303.6% |
| Valuation | ||||||||||||||||
| P/B | 3.57 | 3.57 | 5.22 | 1.20 | 1.95 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -5.5% | -5.5% | 47.6% | 129.5% | — | -77.9% | -20.4% | 133.3% | 277.9% | -90.9% | -17.1% | 237.9% | -71.7% | 91.2% | 3.1% | — |
| EPS Growth | 59.1% | 59.1% | 0.0% | 26.7% | — | — | — | — | — | 58.8% | 45.2% | 16.2% | -15.6% | 88.0% | 80.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.22 → -0.09
Residual
-3.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.